AngioDynamics reports Q4 adjusted EPS (3c), consensus (12c)

Reports Q4 revenue $80.2M, consensus $74.26M. “Our strong Q4 performance capped off a landmark year at AngioDynamics (ANGO). We continue to see the positive impacts of our strategic transformation which has enabled us to deliver accelerating topline growth and continued profitability,” said CEO Jim Clemmer. “For Q3 in a row, we posted MedTech growth of over 20% as our unique, innovative platform technologies across both cardiology and interventional oncology continue to take share in highly competitive global markets. That growth, in combination with our operational efficiency efforts, resulted in positive adjusted EBITDA and significant free cash flow despite experiencing some tariff-related headwinds. During FY25, we made significant strides across the organization as we continue to seek to further simplify our business and focus on penetrating large, fast-growing global MedTech markets. Throughout the year, we achieved key regulatory milestones, expanded into new geographies, generated high-quality clinical data, and secured critical reimbursement pathways. The breadth of these accomplishments – from NanoKnife’s FDA prostate indication and CPT Category I code to AlphaVac’s successful commercial launch and Auryon’s European expansion – reflects our ability to execute across multiple fronts simultaneously”.